KR890001554A - 시클로덱스트린을 함유하는 항비루스성 약제 조성물 - Google Patents

시클로덱스트린을 함유하는 항비루스성 약제 조성물 Download PDF

Info

Publication number
KR890001554A
KR890001554A KR1019880007902A KR880007902A KR890001554A KR 890001554 A KR890001554 A KR 890001554A KR 1019880007902 A KR1019880007902 A KR 1019880007902A KR 880007902 A KR880007902 A KR 880007902A KR 890001554 A KR890001554 A KR 890001554A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
amino
pharmaceutical composition
hydrogen
Prior art date
Application number
KR1019880007902A
Other languages
English (en)
Inventor
엘. 메센스 제인
제이. 엘. 엠. 인드리에스 코엔라아드
Original Assignee
폴 아드리안 쟌 쟈안센
쟈안센 파아마슈우티카 엔.부이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 아드리안 쟌 쟈안센, 쟈안센 파아마슈우티카 엔.부이. filed Critical 폴 아드리안 쟌 쟈안센
Publication of KR890001554A publication Critical patent/KR890001554A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

시클로텍스트린을 함유하는 항비루스성 약제 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 시클로텍스트린과 일반식(I)의 항비루스성 화합물, 그 산부가염, 그 입체화학 이성체 또는 그 호변 이성체로 이루어진 항비루스성 전염병 치료제인 약제 조성물. 단, 시클로텍스트린이 γ-시클로텍스트린 에테르 또는 혼합에테르이고, 에테르 치환제가 C1-6알킬, 히드록시, C1-6알킬, 카르복시 C1-6알킬 또는 (C|1-6알킬 옥시카르보닐) C1-6알킬인 경우 일반식(I)의 화합물인 약제가 아니다.
    상기 일반식(I)에서, R1은 수소, 할로, 1H-이미다졸-1-일. C1-6알킬옥시, 아릴옥시, 아릴C1-6알킬옥시, C1-6알킬티오, 아릴티오, 히드록시, 메르캅토, 아미노 C1-6알킬술포닐, 시아노, C1-6알킬옥시카르보닐, C1-6알킬카르보닐 또는 C1-6알킬이고, R2와 R3는 각각 수소 또는 C1-6알킬이거나, R2와 R3가 결합하여 식 -CH=CH-CH=CH-의 2가 기를 형성할 수 있고, A는
    -CH=N-CH=CH- (a)
    -CmH2m-N(R4-CnH2n- (b)
    -CmH2m-C(R5R6-CnH2n- (c), 또는
    -Cm-1H2(m-1)-C(R7)=C(R8)-CnH2n- (d)의 기이고, 상기 CnH2n, Cn-1H2(m-1) 또는 CmH2m기 내의 수소원자 1개는 C1-6알킬 또는 아릴과 치환될 수 있고, m은 n은 각각 1 내지 4의 정수이고, m과 n의 합은 3,4 또는 5이고, R4는 수소, C1-6알킬, 아릴, 티리아졸릴, 피리미디닐, 퀴노리닐, C1-6알킬카르보닐, C1-6알킬옥시카그보닐, 아릴 C1-6알킬, 디아릴 C1-6알킬, 아릴카르보닐로 치환된 페닐 : 피리디닐 : 시아노 또는 C1-6알킬로 치환된 피리디닐 : 시클로헥실, 시클로헥세닐이거나, 시아노 및 아릴 중에서 선택 치환되는 시클로헥실 또는 시클로헥시닐이고, R5는 수소, C1-6알킬, 아릴 히드록시, C1-6알킬옥시, 아릴옥시 : 모르폴린, 피롤리딘 또는 피페리딘으로 치환된 C1-6알킬옥시 : 아미노(C1-6알킬 옥시카르보닐) 아미노, 아릴아미노, (아릴)(C1-6알킬)아미노, (아릴 C1-6알킬) 아미노, (아릴-C1-6알케닐) 아미노, (아릴-C1-2알케닐)아미노, (아릴 C1-2알케닐)(C1-6알킬) 아미노, 아릴카르보닐옥시이고, R6는 수소, 아릴, C1-6알킬, (C1-6알킬카르보닐아미노)-C1-6알킬, 아릴 C1-6알킬, 아릴카르보닐 C1-6알킬, 아미노카르보닐, 아릴카르보닐, 아릴아미노카르보닐, (아릴 C1-6알킬)카르보닐, C1-6알킬옥시카르보닐, 인들릴, 피리디닐이고, R7과 R8는 각각 수소, C1-6알킬, 아릴, 아릴C1-6알킬, 피리디닐이며, 상기 아릴은 페닐인데, 이는 할로, C1-6알킬, 트리플루오로메틸, 니트로, 아미노, C1-6알킬옥시, 히드록시, C1-6알킬옥시카르보닐, 티에닐 및 나프탈레닐 중에서 선택한 3개 이하의 치환기로 치환될 수 있다.
  2. 제1항에 있어서, 항바이루스제가 소수성 비펩티드제(hydrophobic nonpetide agent)인 약제 조성물.
  3. 제2항에 있어서, 시클로텍스트린이 β 또는 γ-시클로텍스트린에테르 또는 혼합에테르이고, 에테르의 치환기는 C1-6알킬, 히드록시, C1-6알킬, 카르복시, C1-6알킬 또는 (C1-6알킬옥시카르보닐) C1-6알킬인 약제 조성물.
  4. 제3항에 있어서, 에테르의 치환기가1-3알킬, 히드록시 C2-4알킬 또는 카르복시 C1-2알킬인 약제 조성물.
  5. 제3항에 있어서, 치환도(DS)가 0.125 내지 3이고, 몰치환평균(MS)가 0.3 내지 3인 약제 조성물.
  6. 제1항 또는 제5항의 어느 한 항에 있어서, 시클로텍스트린 : 항비루스제의 몰비가 1:1 내지 5:1 인 약제 조성물.
  7. 제1항 또는 제6항의 어느 한 항에 있어서, 항비루스가 다음 일반식(I)의 화합물
    상기 일반식(I)에서, R1은 수소, 할로, 1H-이미다졸-1-일, C1-6알킬옥시, 아릴옥시, 아릴C1-6알킬옥시, C1-6알킬티오, 아릴티오, 히드록시, 메르캅토, 아미노 C1-6알킬술포닐, C1-6알킬술포닐, 시아노, C1-6알킬옥시카르보닐, C1-6알킬카르보닐 또는 C1-6알킬이고, R2와 R3는 각각 수소 또는 C1-6알킬이거나, R2와 R3가 결합하여 식 -CH=CH-CH=CH-의 2가기를 형성할 수 있고, A는
    -CmH2m-N(R4-CnH2n- (b)
    -CmH2m-C(R5R6-CnH2n- (c), 또는
    -Cm-1H2(m-1)-C(R7)=C(R8)-CnH2n- (d)의 기이고, C1-6알킬, 아릴, C1-6알킬, 아미노카르보닐, 아릴카르보닐, 아릴아미노카르보닐, (아릴 C1-6알킬)카르보닐, C1-6알킬옥시 카르보닐, 인돌릴, 피리디닐이고, R7과 R8은 각각 수소, C1-6알킬, 아릴, 아릴 C1-6알킬, 피리디닐이며, 상기 아릴은 페닐인데, 이는 할로, C1-6알킬, 트리플루오로메틸, 니트로, 아미노, C1-6알킬옥시, 히드록시, C1-6알킬옥시카르보닐, 티에닐 및 나프탈레닐중에서 선택한 3개 이하의 치환기로 치환될 수 있다.
  8. 제7항에 있어서, 항비루스제가 3-클로로-6-[3,6-디히듣로-4-(3-메틸페닐)-1(2H)-피리디닐]피리디진 : 3-클로로-6-[3-[3-(트리플로오로메틸)페닐]-1-피톨리디닐]피리다진 :3-메틸-6-[3-[3-(트리플루오로메틸)페닐]-1-피톨리디닐]피리다진 :3-요도-6-[3-[3-(트리플루오로메틸)페닐]-1-피톨리디닐]피리다진 : 3-브로모-6-[3-[3-(트리풀루오로메틸)페닐]-1-피톨리디닐]피리다진 : 3-[3,6-디히드로-4-(3-메틸페닐)-1(2H)-피리디닐]-6-메톡시피리다진 : 3-메톡시-6-[4-[3-(메톡시페닐)페닐]-1-피페라지닐]피리다진 :3-보로모-6-[4-[3-(메틸페닐)-1-피페라지닐]피리다진인 약제 조성물.
  9. 항비루스 약제 조성물(제1항 또는 제8항의 어느 한 항의 조성물)을 함유하는 분무제.
  10. 시클로텍스트린과 항비루스성 약제를 균일하게 혼합하고 임의로 약제성분을 조성하여 약제 조성물(제1항 또는 제8항의 어느 한 항의 약제 조성물)을 제조하는 벙법.
  11. 시클로텍스트린을 물에 용해시키고 항비루스성 화합물을 가한 후 임의로 용액을 건조시켜 약제 조성물(제1항 또는 제8항의 어느 한 항의 약제 조성물)을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880007902A 1987-07-01 1988-06-29 시클로덱스트린을 함유하는 항비루스성 약제 조성물 KR890001554A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6851287A 1987-07-01 1987-07-01
US068,512 1987-07-01

Publications (1)

Publication Number Publication Date
KR890001554A true KR890001554A (ko) 1989-03-27

Family

ID=22083057

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880007902A KR890001554A (ko) 1987-07-01 1988-06-29 시클로덱스트린을 함유하는 항비루스성 약제 조성물

Country Status (16)

Country Link
US (1) US4956351A (ko)
EP (1) EP0300526A3 (ko)
JP (1) JPS6445319A (ko)
KR (1) KR890001554A (ko)
AU (1) AU611692B2 (ko)
CA (1) CA1322172C (ko)
DK (1) DK360988A (ko)
FI (1) FI883136A (ko)
HU (1) HU204705B (ko)
IL (1) IL86910A0 (ko)
NO (1) NO882926L (ko)
NZ (1) NZ225045A (ko)
PH (1) PH26159A (ko)
PT (1) PT87880A (ko)
RU (1) RU2016567C1 (ko)
ZA (1) ZA884747B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
JO1645B1 (en) * 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
IL100856A (en) * 1991-02-15 1998-03-10 Janssen Pharmaceutica Nv History of carboxyl (alkyloxyalkyl of cyclodextrins, their preparation and pharmaceutical preparations containing them
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
US5321014A (en) * 1991-06-28 1994-06-14 The United States Of America As Represented By The Department Of Health And Human Services Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells
US5254541A (en) * 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indole/cyclodextrin complex
DE4204315A1 (de) * 1992-02-13 1993-08-19 Consortium Elektrochem Ind Cyclodextringlycoside und verfahren zu ihrer herstellung
JPH08503951A (ja) * 1992-12-02 1996-04-30 インサイト・ビジョン・インコーポレイテッド シクロデキストリンとポリマーを用いた薬剤供給系
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
DE4333598A1 (de) * 1993-10-01 1995-04-06 Consortium Elektrochem Ind Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten, nach dem Verfahren herstellbare methylierte Cyclodextrin-Derivate und die Verwendung der Produkte
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
DE10203999A1 (de) * 2002-02-01 2003-08-14 Nutricia Nv Cycloglycane
WO2003080080A1 (en) * 2002-03-21 2003-10-02 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
US8158609B1 (en) * 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
RU2448120C1 (ru) * 2010-11-01 2012-04-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратные комплексы бета-циклодекстрина с 1-{[6-бром-1-метил-5-метокси-2-фенилтиометил-1-н-индол-3-ил]карбонил}-4-бензилпиперазином, обладающие противовирусной активностью, их получение и применение
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2464042C1 (ru) * 2011-03-31 2012-10-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
AU2017224249A1 (en) 2016-02-28 2018-09-13 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
ES2968462T3 (es) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE DISEASE
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR64915B (en) * 1978-09-14 1980-06-09 Janssen Pharmaceutica Nv Improved etomidate-containing compositions
HU194858B (en) * 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
HUT47433A (en) 1989-03-28
RU2016567C1 (ru) 1994-07-30
DK360988A (da) 1989-01-02
EP0300526A2 (en) 1989-01-25
FI883136A (fi) 1989-01-02
AU611692B2 (en) 1991-06-20
NZ225045A (en) 1990-06-26
EP0300526A3 (en) 1989-04-12
PT87880A (pt) 1989-06-30
DK360988D0 (da) 1988-06-30
HU204705B (en) 1992-02-28
AU1835288A (en) 1989-01-05
CA1322172C (en) 1993-09-14
PH26159A (en) 1992-03-18
NO882926D0 (no) 1988-06-30
ZA884747B (en) 1990-03-28
IL86910A0 (en) 1988-11-30
JPS6445319A (en) 1989-02-17
NO882926L (no) 1989-01-02
US4956351A (en) 1990-09-11
FI883136A0 (fi) 1988-06-30

Similar Documents

Publication Publication Date Title
KR890001554A (ko) 시클로덱스트린을 함유하는 항비루스성 약제 조성물
KR910019989A (ko) 비스-아릴 아미드 및 우레아 화합물들, 이들로 구성된 조성물 이들을 이용한 paf 억제 방법 및 이들의 생산 방법
JP2005533897A5 (ko)
ES457745A1 (es) Procedimiento para la preparacion de nuevas fluoracil-resor-cinas sustituidas.
ES482004A1 (es) Procedimiento para la preparacion de nuevos derivados 5-fe- nilpirazolicos.
KR830005152A (ko) N-페닐피라졸 유도체의 제조방법
KR880011147A (ko) 트리아졸론 유도체
KR930002311A (ko) N-페닐티오우레아 유도체 및 그의 약학적 용도
KR920019738A (ko) 아미디노페닐알라닌 유도체, 이의 제조방법, 용도 및 이를 함유하는 조성물
KR840004345A (ko) 피라졸 유도체 및 그것의 제조방법과 유효성분으로서 그것을 함유하는 선택적인 제초조성물, 그리고 그것을 사용하여 잡초를 제거하고 억제하는 방법.
ES8704917A1 (es) Procedimiento para prepararar derivados de 1-piperazinacarboximida.
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
CS52684A2 (en) Prostredek proti roztocum, molici sklenikove a trasnenkovitym a zpusob vyroby ucinnych latek
KR890006587A (ko) 살균제 피리딜 시클로프로판 카르복스아미딘 및 세균제어방법
EP0049565A3 (en) Derivatives of substituted n-alkylimidazoles, their preparation and pharmaceutical compositions containing them
KR880002828A (ko) 디하이드로피리딘 유도체 및 이것의 약학적 조성말
KR950010873A (ko) 화장품
KR840006481A (ko) 테트라졸화합물의 제조방법 및 이들화합물을 유효성분으로 하는 항균 및 항미 조성물
KR890003692A (ko) 1.2.5.6- 테트라히드로피리딘-3-카르복스알데히드의 옥심유도체, 이들의 제조방법, 약제로서의 이들의 용도 및 이들을 함유하는 조성물
KR900014339A (ko) 헤테로시클릭 화합물, 그의 제조방법, 이를 함유하는 제약 조성물 및 의약으로서의 용도
KR970704463A (ko) 스트렙토그라민 유도체, 이의 제조 방법 및 이를 함유하는 약학 조성물(streptogramine derivatives, preparation of same and pharmaceutical compositions containing same)
KR880001612A (ko) 신규한 펜옥시 유도체, 그들의 제조방법 및 그들을 함유하는 약제학적 조성물
AU1525683A (en) (+)-cyanidan-3-ol derivatives
KR950030805A (ko) 고형 살생물성 농축 조성물
KR850000456A (ko) 세팔로스포린 에스테르의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application